Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.

This content is available also in other languages

x

This content is available also in other languages

January 23, 2002 | Customer News

Tecan to demonstrate new products at LabAutomation2002 in Palm Springs, USA

  • Extensive range of products on display that target key markets in Genomics, Proteomics, Drug Discovery and Diagnostics
  • Demonstrations available for Impulse, LabCD and Proteam FFE — breakthrough solutions for Drug Discovery and Proteomics
  • Tecan to complete acquisitions of Dr Weber GmbH and CST Logic GmbH

Zurich, Switzerland, 23 January 2002 –  Tecan, a leading player in the fast-growing Life Sciences supply industry, today announced that it will demonstrate new solutions for the Life Sciences at the 2002 LabAutomation * meeting in Palm Springs, USA. The LabAutomation conference is the premier international meeting for scientists, technology specialists, industry decision makers and management interested in emerging laboratory technologies. On display will be a wide range of products targeting high growth markets in Tecan’s four business areas of Genomics, Proteomics, Drug Discovery and Diagnostics.

Emile Sutcliffe, Chief Executive Officer of the Tecan Group, commented:” LabAutomation is a unique event in the calendar of professionals interested in the latest developments in laboratory automation. As such, it is the ideal opportunity for Tecan to demonstrate not only the strength of its existing solutions for the Life Sciences but also its new products that are transforming the practice of high throughput laboratory science.”

New products on display will include the Proteam FFE, for the rapidly growing Proteomics market, and Impulse, an innovative technology for high throughput drug discovery applications. The Proteam FFE is the first addition to Tecan’s ProTeam suite, a range of products that will provide a full complement of solutions to proteomic researchers. Using proprietary free-flow electrophoresis technology, the Proteam FFE enables researchers to reduce the complexity of samples before further analysis. This is achieved through liquid fractionation of cells, organelles and complex protein mixtures before proceeding with procedures such as two-dimensional gel electrophoresis (2D PAGE). The Proteam FFE offers academic, biotech and pharmaceutical companies a much needed pre-analytic solution to increase the sensitivity of their proteomic research.

Impulse, a pipetting technology for Tecan Drug Discovery solutions, is specifically designed to cater for the revolution in miniaturization that is driving developments in drug discovery. Impulse is a technology used with a 384-tip pipetting head that allows samples to be delivered down to the nanoliter range (0.05–50 μl). As such, it is an ideal solution for applications in high throughput drug screening processes.

Multimedia presentations will be given to demonstrate Tecan’s solutions for cell maintenance, cell permeability, DNA extraction and in-gel sample digestion. In addition, Tecan representatives will be present to discuss forthcoming solutions that include Tecan’s EasySNP FP detection system (for the detection of single nucleotide polymorphisms or SNPs), the Microarray Hybridization Station (for oligonucleotide-, cDNA-, protein- and antibody-based array applications) and the LabCD™, Tecan’s revolutionary microfluidic technology that eliminates key bottlenecks in drug discovery.

In addition to new products, Tecan will display many of its existing solutions that have contributed to the success of the company as a leading provider to the Life Sciences. These range from products marking the entry of Tecan into the field of array applications, for example the LS series of microarray scanners, to drug discovery detection devices such as Safire and Ultra 384. Core platform technologies applicable to all markets complete the products on show. This includes the Genesis Freedom on which many Tecan solutions are based.

To further strengthen its core competencies, Tecan also announced that it is proceeding with the completion of two acquisitions. This includes the acquisitions of CST Logic GmbH, a provider of integrated and customized software solutions for laboratory automation and data management, and Dr Weber GmbH, a company that specializes in the proprietary free-flow electrophoresis technology that is central to Tecan’s solutions in proteomics. In January 2001, Tecan acquired a majority share in Dr Weber GmbH. The remaining assets of the company will be acquired through Tecan Munich GmbH, formerly Tecan Proteomics GmbH, a subsidiary of Tecan situated in Munich, Germany.

CST Logic GmbH, which was founded in 1995, is a German company that specializes in the development of software for laboratory automation and data management. The company, which is situated in Mainz-Kastel, has worked closely with Tecan for many years and developed the FACTS event scheduling software, an integral part of some Tecan workstations. CST Logic GmbH employs 13 software developers and had a turnover of 1.45 million Euros in 2001. Tecan will acquire 100% of the stock of CST Logic GmbH. Both acquisitions will be completed by the end of February this year.

Emile Sutcliffe, Chief Executive Officer of the Tecan Group, commented: “LabAutomation2002 is the perfect occasion for Tecan to demonstrate the outstanding progress we have made in delivering solutions to the Life Sciences. We look forward to meeting our partners in Palm Springs.”

Tecan (www.tecan.com) is a leading player in the fast growing Life Sciences supply industry that specializes in the development, production, and distribution of solutions enabling the discovery of pharmaceutical substances, as well as for genomics, proteomics, and diagnostics. Tecan clients are leading pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2000, Tecan achieved sales of CHF 273.5 million (USD 162 million; EUR 175 million). Registered shares of Tecan Group are traded on the Swiss SWX stock exchange (TK: TECN / Reuters: TECZn.S / Valor : 707821).

For more information, please contact :

Product information:

Tecan Group Ltd.
Cornelia Kegele
Manager Marketing Communications and Branding
Tel.: +41 (0)44 922 81 11
Fax: +41 (0)44 922 82 81
e-mail: cornelia.kegele@tecan.com
Internet: www.tecan.com

 * LabAutomation will take place on January 26–30, 2002. More details are available at http://www.slas.org